1. Home
  2. SEPN vs HSII Comparison

SEPN vs HSII Comparison

Compare SEPN & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEPN
  • HSII
  • Stock Information
  • Founded
  • SEPN 2022
  • HSII 1953
  • Country
  • SEPN United States
  • HSII United States
  • Employees
  • SEPN N/A
  • HSII N/A
  • Industry
  • SEPN
  • HSII Diversified Commercial Services
  • Sector
  • SEPN
  • HSII Consumer Discretionary
  • Exchange
  • SEPN NYSE
  • HSII Nasdaq
  • Market Cap
  • SEPN 1.0B
  • HSII 931.5M
  • IPO Year
  • SEPN 2024
  • HSII 1999
  • Fundamental
  • Price
  • SEPN $22.40
  • HSII $46.05
  • Analyst Decision
  • SEPN Strong Buy
  • HSII Buy
  • Analyst Count
  • SEPN 4
  • HSII 2
  • Target Price
  • SEPN $43.67
  • HSII $46.00
  • AVG Volume (30 Days)
  • SEPN 237.6K
  • HSII 136.1K
  • Earning Date
  • SEPN 02-15-2025
  • HSII 11-04-2024
  • Dividend Yield
  • SEPN N/A
  • HSII 1.32%
  • EPS Growth
  • SEPN N/A
  • HSII N/A
  • EPS
  • SEPN N/A
  • HSII 1.83
  • Revenue
  • SEPN $981,000.00
  • HSII $1,075,544,000.00
  • Revenue This Year
  • SEPN N/A
  • HSII $7.80
  • Revenue Next Year
  • SEPN N/A
  • HSII $2.89
  • P/E Ratio
  • SEPN N/A
  • HSII $24.82
  • Revenue Growth
  • SEPN N/A
  • HSII 6.55
  • 52 Week Low
  • SEPN $18.62
  • HSII $26.52
  • 52 Week High
  • SEPN $27.47
  • HSII $49.02
  • Technical
  • Relative Strength Index (RSI)
  • SEPN N/A
  • HSII 52.92
  • Support Level
  • SEPN N/A
  • HSII $44.55
  • Resistance Level
  • SEPN N/A
  • HSII $46.04
  • Average True Range (ATR)
  • SEPN 0.00
  • HSII 1.16
  • MACD
  • SEPN 0.00
  • HSII -0.28
  • Stochastic Oscillator
  • SEPN 0.00
  • HSII 32.20

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

About HSII Heidrick & Struggles International Inc.

Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.

Share on Social Networks: